Video

Q&A with Alain Litwin, MD, from Albert Einstein College of Medicine: Studying and Overcoming Stigmas of Treating Injectable Drug Users with Hepatitis C

Author(s):

One of the largest populations of patients with hepatitis C is those who use injectable drugs. Despite this, many of these patients do not receive the medications they need to treat their conditions.

One of the largest populations of patients with hepatitis C is those who use injectable drugs. Despite this many of these patients do not receive the medications they need to treat their conditions.

Alain H. Litwin, MD, from the Albert Einstein College of Medicine discussed the results of research done on the topic and what it can mean for providing care for these patients during the annual Liver Meeting in San Francisco.

As hepatitis C becomes a more treatable condition work is being done to extend the treatment to as many patients as possible, including current and former injectable drug users.

Related Videos
Brigit Vogel, MD: Exploring Geographical Disparities in PAD Care Across US| Image Credit: LinkedIn
Eric Lawitz, MD | Credit: UT Health San Antonio
| Image Credit: X
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Stephen Nicholls, MBBS, PhD | Credit: Monash University
Marianna Fontana, MD, PhD: Nex-Z Shows Promise in ATTR-CM Phase 1 Trial | Image Credit: Radcliffe Cardiology
Zerlasiran Achieves Durable Lp(a) Reductions at 60 Weeks, with Stephen J. Nicholls, MD, PhD | Image Credit: Monash University
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
A. Sidney Barritt, MD | Credit: UNC School of Medicine
© 2024 MJH Life Sciences

All rights reserved.